NIH launches clinical trial for hospital patients, antibody research network
The National Institutes of Health has launched a global clinical trial to test a potential COVID-19 treatment that combines remdesivir with a highly concentrated antibody solution. The phase 3 trial will enroll 500 hospitalized adults who have had COVID-19 symptoms for 12 or fewer days and no serious organ dysfunction, and compare their health status after the combination treatment with participants receiving remdesivir and a placebo. The agency also announced a research network to study the immune response to COVID-19 and increase antibody testing capacity.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…